Mechanisms of neurotransmitter release by amphetamines: A review

  title={Mechanisms of neurotransmitter release by amphetamines: A review},
  author={David L. Sulzer and Mark S. Sonders and Nathan W. Poulsen and Aurelio Galli},
  journal={Progress in Neurobiology},

Figures from this paper

New insights into the mechanism of action of amphetamines.
New insights are obtained into the molecular mechanisms whereby amphetamine, and the closely related compounds methamphetamine and methylenedioxymethamphetamine, cause monoamine, and particularly dopamine, release, which have potential implications for both amphetamine- and methamphetamine-induced neurotoxicity, as well as dopaminergic neurodegenerative diseases.
Amphetamines, new psychoactive drugs and the monoamine transporter cycle
Toxicity of amphetamines: an update
The long-studied classical amphetamines—amphetamine itself, as well as methamphetamine and MDMA provide plenty of data that may be useful to predict toxicological outcome to improvident abusers and are for that reason the main focus of this review.
Amphetamine Derivatives as Monoamine Oxidase Inhibitors
This work reviews how structural modifications on the aromatic ring, the amino group and/or the aliphatic side chain of the parent scaffold, modulate the enzyme inhibitory properties of hundreds of amphetamine derivatives.
Molecular Mechanisms of Amphetamines.
There is a plethora of amphetamine derivatives exerting stimulant, euphoric, anti-fatigue, and hallucinogenic effects; all structural properties allowing these effects are contained within the
The Epigenetic Mechanisms of Amphetamine.
A review examines the epigenetic changes induced by chronic and acute treatments with AMPH and includes, where relevant, data obtained with other psychostimulants such as methamphetamine and cocaine.
Mitochondria: key players in the neurotoxic effects of amphetamines
Understanding the molecular mechanisms at mitochondrial level involved in amphetamines’ neurotoxicity can help in defining target pathways or molecules mediating these effects, as well as in developing putative therapeutic approaches to prevent or treat the acute- or long-lasting neuropsychiatric complications seen in human abusers.
Amphetamine toxicities
Overall, multiple mechanisms are involved and interact to promote neurotoxicity to methamphetamine and MDMA and the high coincidence of substituted amphetamine abuse by humans with HIV and/or chronic stress exposure suggests a potential enhanced vulnerability of these individuals to the neurotoxic actions of the amphetamines.
Methamphetamine, neurotransmitters and neurodevelopment.
Current understanding in role of NEUs, which are affected by MA-induced neurotoxicity caused by altering the action ofNEUs in the central nervous system (CNS), is described and information about NEUs development in critical periods of development is brought.
The neurotoxicity of amphetamines during the adolescent period


Amphetamine induces dopamine efflux through a dopamine transporter channel.
It is reported that AMPH causes DAT-mediated DA efflux by two independent mechanisms: a slow process consistent with an exchange mechanism and a process that results in rapid (millisecond) bursts ofDA efflux through a channel-like mode of DAT.
Amphetamines take two to tango: an oligomer-based counter-transport model of neurotransmitter transport explores the amphetamine action.
It is proposed that, in the presence of amphetamine analogs, monoamine transporters operate as counter-transporters; influx and efflux occur through separate but coupled moieties.
Weak Base Model of Amphetamine Action
A model for the action of AMPH is suggested and a crucial prediction has now been borne out: weak bases that are not abused act like AMPH when applied directly to the nucleus accumbens or cultured DA neurons.
Amphetamines: Structure-Activity Relationships
Clinically, amphetamine has been used as a stimulant, antidepressant, and appetite suppressant, but with repeated administration tolerance frequently develops to many of its effects.
Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor.
The discovery and pharmacological characterization of a rat G protein-coupled receptor that stimulates the production of cAMP when exposed to the trace amines p-tyramine, beta-phenethylamine, tryptamine, and octopamine and the discovery that amphetamines are potent rTAR1 agonists suggests that the effects of these widely used drugs may be mediated in part by this receptor as well as their previously characterized targets, the neurotransmitter transporter proteins.
Inhibition of monoamine oxidase by amphetamine and related compounds.
Amphetamine Distorts Stimulation-Dependent Dopamine Overflow: Effects on D2 Autoreceptors, Transporters, and Synaptic Vesicle Stores
Amphetamine (AMPH) is known to raise extracellular dopamine (DA) levels by inducing stimulation-independent DA efflux via reverse transport through the DA transporter and by inhibiting DA re-uptake.
Amphetamine: effects on catecholamine systems and behavior.
The effects of AMPH in humans have close parallels in animals and at low doses, AMPH increases stereotypic locomotor activity and species-specific stereotypies at higher doses and interferes with intake.